Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Author Correction: Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade.

Miller BC, Sen DR, Al Abosy R, Bi K, Virkud YV, LaFleur MW, Yates KB, Lako A, Felt K, Naik GS, Manos M, Gjini E, Kuchroo JR, Ishizuka JJ, Collier JL, Griffin GK, Maleri S, Comstock DE, Weiss SA, Brown FD, Panda A, Zimmer MD, Manguso RT, Hodi FS, Rodig SJ, Sharpe AH, Haining WN.

Nat Immunol. 2019 Nov;20(11):1556. doi: 10.1038/s41590-019-0528-5.

PMID:
31582823
2.

Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade.

Miller BC, Sen DR, Al Abosy R, Bi K, Virkud YV, LaFleur MW, Yates KB, Lako A, Felt K, Naik GS, Manos M, Gjini E, Kuchroo JR, Ishizuka JJ, Collier JL, Griffin GK, Maleri S, Comstock DE, Weiss SA, Brown FD, Panda A, Zimmer MD, Manguso RT, Hodi FS, Rodig SJ, Sharpe AH, Haining WN.

Nat Immunol. 2019 Mar;20(3):326-336. doi: 10.1038/s41590-019-0312-6. Epub 2019 Feb 18. Erratum in: Nat Immunol. 2019 Nov;20(11):1556.

3.

Psychometric limitations of the RBANS effort index in forensic inpatient populations.

Williams KD, Hancock E, Wozniak N, Oehler S, Manguso R.

Appl Neuropsychol Adult. 2019 Feb 6:1-7. doi: 10.1080/23279095.2018.1517768. [Epub ahead of print]

PMID:
30724593
4.

Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade.

Ishizuka JJ, Manguso RT, Cheruiyot CK, Bi K, Panda A, Iracheta-Vellve A, Miller BC, Du PP, Yates KB, Dubrot J, Buchumenski I, Comstock DE, Brown FD, Ayer A, Kohnle IC, Pope HW, Zimmer MD, Sen DR, Lane-Reticker SK, Robitschek EJ, Griffin GK, Collins NB, Long AH, Doench JG, Kozono D, Levanon EY, Haining WN.

Nature. 2019 Jan;565(7737):43-48. doi: 10.1038/s41586-018-0768-9. Epub 2018 Dec 17.

PMID:
30559380
5.

An Analysis of the Correlates of Aggression in a Social Learning Program for Severely and Persistently Mentally Ill Inpatients.

Oehler S, Berman A, Gay C, Manguso R, Espinoza J.

Arch Psychiatr Nurs. 2018 Feb;32(1):39-43. doi: 10.1016/j.apnu.2017.09.012. Epub 2017 Sep 28.

PMID:
29413070
6.

Pooled in vivo screens for cancer immunotherapy target discovery.

Lane-Reticker SK, Manguso RT, Haining WN.

Immunotherapy. 2018 Mar;10(3):167-170. doi: 10.2217/imt-2017-0164. No abstract available.

PMID:
29370725
7.

In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target.

Manguso RT, Pope HW, Zimmer MD, Brown FD, Yates KB, Miller BC, Collins NB, Bi K, LaFleur MW, Juneja VR, Weiss SA, Lo J, Fisher DE, Miao D, Van Allen E, Root DE, Sharpe AH, Doench JG, Haining WN.

Nature. 2017 Jul 27;547(7664):413-418. doi: 10.1038/nature23270. Epub 2017 Jul 19.

8.

PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity.

Juneja VR, McGuire KA, Manguso RT, LaFleur MW, Collins N, Haining WN, Freeman GJ, Sharpe AH.

J Exp Med. 2017 Apr 3;214(4):895-904. doi: 10.1084/jem.20160801. Epub 2017 Mar 16.

9.

Primary cilia and aberrant cell signaling in epithelial ovarian cancer.

Egeberg DL, Lethan M, Manguso R, Schneider L, Awan A, Jørgensen TS, Byskov AG, Pedersen LB, Christensen ST.

Cilia. 2012 Aug 10;1(1):15. doi: 10.1186/2046-2530-1-15.

10.

EB1 and EB3 promote cilia biogenesis by several centrosome-related mechanisms.

Schrøder JM, Larsen J, Komarova Y, Akhmanova A, Thorsteinsson RI, Grigoriev I, Manguso R, Christensen ST, Pedersen SF, Geimer S, Pedersen LB.

J Cell Sci. 2011 Aug 1;124(Pt 15):2539-51. doi: 10.1242/jcs.085852.

Supplemental Content

Loading ...
Support Center